Invivyd Presents Preclinical Data Showing Measles Antibody Candidate VMS063 Demonstrates Potent Antiviral Activity Against Contemporary Measles Fusion Protein Variants

Invivyd, Inc. has presented preclinical data on its investigational monoclonal antibody candidate VMS063, which shows potent antiviral activity against contemporary measles virus variants. This candidate is being developed as a potential first- and best-in-class treatment and prevention option for measles, addressing a significant public health gap as there are currently no FDA-approved treatments for the disease. The company is scaling up production in preparation for clinical development slated for 2027, amid a record number of measles cases in the U.S. in 2026.